Lipocine announces motions decision by USPTO
Lipocine announced that the Patent Trial and Appeal Board, or PTAB, of the United States Patent and Trademark Office issued a Motions Decision based on each party's motions in the interference case, Patent Interference No. 106,045, between Clarus Therapeutics U.S. Patent No. 8,828,428, and Lipocine, U.S. Patent Application No. 14/713,692. The PTAB granted Lipocine's motion to deny Clarus' previously accorded priority date for the '428 Patent. Therefore, Clarus has a new priority date of April 16, 2014 for the Clarus '428 patent. The PTAB also granted Clarus' motion to deny Lipocine's accorded priority date. Therefore, Lipocine's has an accorded priority date of May 15, 2015 for the Lipocine '692 Application. As a consequence of this decision, the PTAB has redeclared the interference and named Clarus as the senior party and Lipocine as the junior party. All other motions were denied. A conference call with the PTAB is scheduled for October 4, 2017 to discuss the next steps, including priority schedule.